API
< Back to all clusters
[HEALTH] · United States · 3 sources

started · updated

ImmunoPET scan detects hidden multiple myeloma lesions

A phase 2 clinical trial has demonstrated that a new immunoPET imaging technique can detect active multiple myeloma that standard FDG-PET/CT scans and blood tests often miss. The study, published in the journal Radiology, involved 60 patients and was led by researchers at the Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, in collaboration with the Hoag Cancer Center.

Unlike traditional PET/CT scans that rely on glucose consumption, the immunoPET method uses a zirconium-89 labeled daratumumab tracer to target the CD38 surface antigen directly on myeloma cells. This approach is significant because myeloma cells often consume glucose at rates similar to healthy cells, leading to false negatives in up to 40% of standard scans.

In the trial, the immunoPET scan identified active disease in 13% of participants (eight out of 60) whose traditional FDG scans were negative. Additionally, the targeted imaging revealed lesions in 17 patients, representing 28% of the study group, that were not visible via standard methods. Subsequent biopsies confirmed the presence of active disease in these cases.

Entities

C. Ola Landgren · Hoag Cancer Center · Radiology · Sylvester Comprehensive Cancer Center · University of Miami Miller School of Medicine